

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date: February 7, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overall			
A.U.	N 9	-		
All	130076 10	00		
Age (in years)	10	_		
0-4	10	0		
5-11	1568	1		
12-17	5973	5		
18-24	11102	9		
25-49		14		
50-64		24		
65+	23671 1	18		
Gender	50700			
Male		14 - 0		
Female		56		
Unknown	967	1		
Race/Ethnicity				
Hispanic		21		
White		32		
Black	10246	8		
API		13		
AEA	451	0		
Other	9208	7		
Unknown	25101 1	19		
Travel History				
Yes	5672	4		
No		28		
Unknown	88408 6	58		
Hospitalization				
Yes	3381	3		
No		31		
Unknown	86054 6	66		
Death				
Yes	1210	1		
No	10068	8		
Unknown	118798 9	91		
Vaccine Type				
Pfizer		67		
Novavax	5	0		
Unknown	1120	1		
Moderna		27		
Janssen	7053	5		
Emergen	1	0		
Underlying Conditions				
Yes		15		
No	110134 8	35		

Table 1: Population Characteristics of COVID-19 Breakthrough Cases

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
877493	130076	1440681	468188	14824	32498



		Overall	
	-	6	
All	3381 10	00	
Age (in years)			
5-11	5	0	
12-17	19	1	
18-24	34	1	
25-49	342 <i>°</i>	10	
50-64	587 ⁻	17	
65+	2394	71	
Gender			
Male	1836 క	54	
Female	1541 4	46	
Unknown	4	0	
Race/Ethnicity			
Hispanic	422	12	
White	1972 క	58	
Black	380	11	
API	332 <i>°</i>	10	
AEA	15	0	
Other	101	3	
Unknown	159	5	
Travel History			
Yes	144	4	
No	1733 క	51	
Unknown	1504 4	44	
Death			
Yes	856 2	25	
No	608 ⁻	18	
Unknown	1917 క	57	
Vaccine Type			
Pfizer	1963	58	
Unknown	86	3	
Moderna	1082 (32	
Janssen	250	7	
Underlying Conditions			
Yes	2438	72	
No	943 2	28	



	Over	Overall	
	Ν	%	
All	1210	100	
Age (in years)			
25-49	37	3	
50-64	145	12	
65+	1028	85	
Gender			
Male	729	60	
Female	481	40	
Race/Ethnicity			
Hispanic	131	11	
White	815	67	
Black	127	10	
API	115	10	
AEA	6	0	
Other	10	1	
Unknown	6	0	
Hospitalization			
Yes	856	71	
No	77	6	
Unknown	277	23	
Vaccine Type			
Pfizer	664	55	
Unknown	29	2	
Moderna	395	33	
Janssen	122	10	
Underlying Conditions			
Yes	694	57	
No	516	43	

Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

Table 5: Breakthrough Death Rates

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
877493	1210	1440681	8082	138	561

* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	2438	72
	No	943	28
Hypertension	Yes	1558	N/A
Immunocompromised	Yes	137	N/A
Chronic Heart Disease	Yes	730	N/A
Chronic Liver Disease	Yes	63	N/A
Chronic Kidney Disease	Yes	479	N/A
Diabetes	Yes	914	N/A
Neurologic/Neurodevelopmental	Yes	201	N/A
Chronic Lung Disease	Yes	643	N/A
Historically Healthy	Yes	293	N/A

Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	694	57
	No	516	43
Hypertension	Yes	446	N/A
Immunocompromised	Yes	50	N/A
Chronic Heart Disease	Yes	250	N/A
Chronic Liver Disease	Yes	25	N/A
Chronic Kidney Disease	Yes	188	N/A
Diabetes	Yes	266	N/A
Neurologic/Neurodevelopmental	Yes	61	N/A
Chronic Lung Disease	Yes	198	N/A
Historically Healthy	Yes	26	N/A

Notes:

* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).